Table Graph
   

Non replicating viral vector - versus mRNA vaccine - for COVID-19 prophylaxis (excluding children) pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

safety endpoints 00

adverse events 1.14 [0.78, 1.66]< 10%1 study (1/-)24.7 %NAnot evaluable non important-
intracranial hemorrhage 1.01 [0.02, 51.28]< 10%1 study (1/-)49.7 %NAnot evaluable non important-
ischemic stroke 1.01 [0.02, 51.28]< 10%1 study (1/-)49.7 %NAnot evaluable non important-
Myocardial infarction 1.51 [0.11, 19.72]< 10%2 studies (2/-)37.9 %NAnot evaluable non important-
pulmonary embolism 1.01 [0.02, 51.28]< 10%1 study (1/-)49.7 %NAnot evaluable non important-
serious adverse events (SAE), any 1.53 [0.25, 9.36]< 10%1 study (1/-)32.3 %NAnot evaluable non important-
venous thromboembolism 2.03 [0.07, 61.21]< 10%1 study (1/-)34.4 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons